MX2018005379A - Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico. - Google Patents

Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico.

Info

Publication number
MX2018005379A
MX2018005379A MX2018005379A MX2018005379A MX2018005379A MX 2018005379 A MX2018005379 A MX 2018005379A MX 2018005379 A MX2018005379 A MX 2018005379A MX 2018005379 A MX2018005379 A MX 2018005379A MX 2018005379 A MX2018005379 A MX 2018005379A
Authority
MX
Mexico
Prior art keywords
conjugates
therapeutic use
preparation
cryptophycin compounds
novel cryptophycin
Prior art date
Application number
MX2018005379A
Other languages
English (en)
Inventor
Zhang Jidong
Bouchard Hervé
Bigot Antony
Priscille Brun Marie-
Clerc François
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2018005379A publication Critical patent/MX2018005379A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de criptoficina de fórmula (I). La presente invención también se refiere a cargas útiles de criptoficina, a productos conjugados de criptofocina, a composiciones que los contienen y a su uso terapéutico, especialmente como agentes anticancerosos. La invención también se refiere al procedimiento para la preparación de estos productos conjugados.
MX2018005379A 2015-11-05 2016-11-03 Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico. MX2018005379A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (en) 2015-11-05 2016-11-03 Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
MX2018005379A true MX2018005379A (es) 2018-09-05

Family

ID=54476881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005379A MX2018005379A (es) 2015-11-05 2016-11-03 Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico.

Country Status (35)

Country Link
US (2) US10941139B2 (es)
EP (1) EP3371179B1 (es)
JP (1) JP6929292B2 (es)
KR (1) KR20180073678A (es)
CN (1) CN108349960B (es)
AR (1) AR106604A1 (es)
AU (1) AU2016347724B2 (es)
CA (1) CA3003085A1 (es)
CL (1) CL2018001210A1 (es)
CO (1) CO2018004581A2 (es)
CR (1) CR20180256A (es)
CY (1) CY1122441T1 (es)
DK (1) DK3371179T3 (es)
EA (1) EA035625B1 (es)
EC (1) ECSP18034035A (es)
ES (1) ES2755101T3 (es)
HK (1) HK1256754B (es)
HR (1) HRP20191729T1 (es)
HU (1) HUE046033T2 (es)
IL (1) IL259067B (es)
LT (1) LT3371179T (es)
MA (1) MA43160B1 (es)
MX (1) MX2018005379A (es)
MY (1) MY189448A (es)
PH (1) PH12018500852A1 (es)
PL (1) PL3371179T3 (es)
PT (1) PT3371179T (es)
RS (1) RS59498B1 (es)
SG (1) SG11201803181SA (es)
SI (1) SI3371179T1 (es)
TN (1) TN2018000131A1 (es)
TW (1) TWI714661B (es)
UY (1) UY36979A (es)
WO (1) WO2017076998A1 (es)
ZA (1) ZA201802322B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
MX2019013421A (es) * 2017-05-10 2020-02-05 Sanofi Sa Enlazadores peptidicos y conjugados de criptoficina, utiles en la terapia, y su preparacion.
CN108107103B (zh) * 2017-12-14 2020-10-16 华中师范大学 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法
TW202100506A (zh) 2019-03-07 2021-01-01 美商柯納特斯製藥公司 半胱天冬酶(caspase)抑制劑及其使用方法
EP4038085A1 (en) 2019-09-30 2022-08-10 The Regents of The University of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203016T1 (de) * 1993-12-21 2001-07-15 Univ Hawaii Cryptophycine
US20020128185A1 (en) * 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP2010475A2 (en) 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 epha2에 대한 길항제 항체
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途

Also Published As

Publication number Publication date
MA43160B1 (fr) 2019-12-31
PL3371179T3 (pl) 2020-02-28
TN2018000131A1 (en) 2019-10-04
CN108349960A (zh) 2018-07-31
LT3371179T (lt) 2019-11-11
WO2017076998A1 (en) 2017-05-11
HRP20191729T1 (hr) 2019-12-13
JP6929292B2 (ja) 2021-09-01
EP3371179A1 (en) 2018-09-12
SI3371179T1 (sl) 2019-11-29
NZ741734A (en) 2023-10-27
JP2018535255A (ja) 2018-11-29
CY1122441T1 (el) 2021-01-27
ES2755101T3 (es) 2020-04-21
KR20180073678A (ko) 2018-07-02
EA201890898A1 (ru) 2018-10-31
AU2016347724A1 (en) 2018-05-10
CL2018001210A1 (es) 2018-08-17
CA3003085A1 (en) 2017-05-11
CO2018004581A2 (es) 2018-07-19
CN108349960B (zh) 2022-05-27
TW201730164A (zh) 2017-09-01
AU2016347724B2 (en) 2021-04-01
SG11201803181SA (en) 2018-05-30
BR112018008490A2 (pt) 2019-02-12
ECSP18034035A (es) 2018-05-31
DK3371179T3 (da) 2019-11-11
US20190382391A1 (en) 2019-12-19
ZA201802322B (en) 2019-01-30
UY36979A (es) 2017-06-30
IL259067B (en) 2021-07-29
EA035625B1 (ru) 2020-07-17
TWI714661B (zh) 2021-01-01
HUE046033T2 (hu) 2020-01-28
PT3371179T (pt) 2019-11-18
AR106604A1 (es) 2018-01-31
HK1256754B (zh) 2020-06-05
PH12018500852B1 (en) 2018-10-29
US20210163458A1 (en) 2021-06-03
PH12018500852A1 (en) 2018-10-29
US10941139B2 (en) 2021-03-09
CR20180256A (es) 2018-08-13
IL259067A (en) 2018-06-28
RS59498B1 (sr) 2019-12-31
MY189448A (en) 2022-02-14
EP3371179B1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12018500852A1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
PH12016501791A1 (en) Muscarinic receptor agonists
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MD20150091A2 (ro) Compuşi antivirali
MX2018007319A (es) Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
MX2017014035A (es) Formas solidas novedosas.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
TW201613864A (en) Novel compounds
CR20190519A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
GEP20196944B (en) Process for preparing the inhalation formulations
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration